WO2009054479A1 - スピロ環化合物及びその医薬用途 - Google Patents

スピロ環化合物及びその医薬用途 Download PDF

Info

Publication number
WO2009054479A1
WO2009054479A1 PCT/JP2008/069296 JP2008069296W WO2009054479A1 WO 2009054479 A1 WO2009054479 A1 WO 2009054479A1 JP 2008069296 W JP2008069296 W JP 2008069296W WO 2009054479 A1 WO2009054479 A1 WO 2009054479A1
Authority
WO
WIPO (PCT)
Prior art keywords
spiro
ring compound
medical purposes
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/JP2008/069296
Other languages
English (en)
French (fr)
Inventor
Takashi Shimada
Hiroshi Ueno
Kazuhiro Tsutsumi
Kouichi Aoyagi
Tomoyuki Manabe
Shin-Ya Sasaki
Susumu Katoh
Original Assignee
Japan Tobacco Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40579581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009054479(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2704013A priority Critical patent/CA2704013C/en
Priority to MX2010004435A priority patent/MX2010004435A/es
Priority to RU2010121160/04A priority patent/RU2490250C2/ru
Priority to MEP-2016-195A priority patent/ME02338B/me
Priority to ES08841970T priority patent/ES2386596T3/es
Priority to BRPI0818687A priority patent/BRPI0818687A2/pt
Priority to CN2008801132388A priority patent/CN101835737B/zh
Priority to SI200830752T priority patent/SI2202216T1/sl
Priority to DK08841970.0T priority patent/DK2202216T3/da
Priority to NZ584161A priority patent/NZ584161A/en
Priority to EP08841970A priority patent/EP2202216B1/en
Priority to PL08841970T priority patent/PL2202216T3/pl
Priority to RS20120400A priority patent/RS52474B/en
Priority to AU2008314933A priority patent/AU2008314933B2/en
Application filed by Japan Tobacco Inc. filed Critical Japan Tobacco Inc.
Publication of WO2009054479A1 publication Critical patent/WO2009054479A1/ja
Priority to ZA2010/02305A priority patent/ZA201002305B/en
Priority to IL205283A priority patent/IL205283A/en
Priority to HK10110999.8A priority patent/HK1144421A1/xx
Priority to HRP20120696AT priority patent/HRP20120696T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/50—Spiro compounds

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

　下記一般式［Ｉａ］で表されるスピロ環化合物又はその医薬上許容される塩、或いはその溶媒和物。
PCT/JP2008/069296 2007-10-26 2008-10-24 スピロ環化合物及びその医薬用途 WO2009054479A1 (ja)

Priority Applications (18)

Application Number Priority Date Filing Date Title
DK08841970.0T DK2202216T3 (da) 2007-10-26 2008-10-24 Spiro-ringforbindelse samt dens anvendelse til medicinske formål
AU2008314933A AU2008314933B2 (en) 2007-10-26 2008-10-24 Spiro-ring compound and use thereof for medical purposes
RU2010121160/04A RU2490250C2 (ru) 2007-10-26 2008-10-24 Спиросоединения и их фармацевтическое применение
MEP-2016-195A ME02338B (me) 2007-10-26 2008-10-24 Spiro-ciklično jedinjenje i njegova upotreba u medicinske svrhe
ES08841970T ES2386596T3 (es) 2007-10-26 2008-10-24 Compuesto espiro-anillo y su uso para fines médicos
BRPI0818687A BRPI0818687A2 (pt) 2007-10-26 2008-10-24 composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
CN2008801132388A CN101835737B (zh) 2007-10-26 2008-10-24 螺环化合物及其药学用途
EP08841970A EP2202216B1 (en) 2007-10-26 2008-10-24 Spiro-ring compound and use thereof for medical purposes
NZ584161A NZ584161A (en) 2007-10-26 2008-10-24 Spiro-ring compound and use thereof for medical purposes
CA2704013A CA2704013C (en) 2007-10-26 2008-10-24 Spiro compounds and pharmaceutical use thereof
SI200830752T SI2202216T1 (sl) 2007-10-26 2008-10-24 Spiro obročna spojina in njena uporaba za medicinske namene
PL08841970T PL2202216T3 (pl) 2007-10-26 2008-10-24 Związek spirocykliczny i jego zastosowanie do celów medycznych
RS20120400A RS52474B (en) 2007-10-26 2008-10-24 SPIRO-CYCLIC UNIT AND ITS USE IN MEDICAL PURPOSES
MX2010004435A MX2010004435A (es) 2007-10-26 2008-10-24 Compuestos espiro y uso farmaceutico de los mismos.
ZA2010/02305A ZA201002305B (en) 2007-10-26 2010-03-31 Spiro-ring compound and use thereof for medical purposes
IL205283A IL205283A (en) 2007-10-26 2010-04-22 Spiro ring and its use for medical purposes
HK10110999.8A HK1144421A1 (en) 2007-10-26 2010-11-26 Spiro-ring compound and use thereof for medical purposes
HRP20120696AT HRP20120696T1 (hr) 2007-10-26 2012-09-04 Spiro-prstenasti spoj i njegova medicinska upotreba

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-279697 2007-10-26
JP2007279697 2007-10-26
US182307P 2007-11-05 2007-11-05
US61/001,823 2007-11-05

Publications (1)

Publication Number Publication Date
WO2009054479A1 true WO2009054479A1 (ja) 2009-04-30

Family

ID=40579581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069296 WO2009054479A1 (ja) 2007-10-26 2008-10-24 スピロ環化合物及びその医薬用途

Country Status (30)

Country Link
US (3) US8299296B2 (ja)
EP (3) EP2202216B1 (ja)
JP (5) JP4568779B2 (ja)
KR (1) KR101565622B1 (ja)
CN (1) CN101835737B (ja)
AR (1) AR071055A1 (ja)
AU (1) AU2008314933B2 (ja)
BR (1) BRPI0818687A2 (ja)
CA (1) CA2704013C (ja)
CL (1) CL2008003153A1 (ja)
CO (1) CO6321230A2 (ja)
CY (1) CY1113352T1 (ja)
DK (1) DK2202216T3 (ja)
ES (1) ES2386596T3 (ja)
HK (1) HK1144421A1 (ja)
HR (1) HRP20120696T1 (ja)
IL (1) IL205283A (ja)
ME (1) ME02338B (ja)
MX (1) MX2010004435A (ja)
MY (1) MY148469A (ja)
NZ (1) NZ584161A (ja)
PE (1) PE20091014A1 (ja)
PL (1) PL2202216T3 (ja)
PT (1) PT2202216E (ja)
RS (1) RS52474B (ja)
RU (1) RU2490250C2 (ja)
SI (1) SI2202216T1 (ja)
TW (1) TWI421070B (ja)
WO (1) WO2009054479A1 (ja)
ZA (1) ZA201002305B (ja)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009157418A1 (ja) * 2008-06-25 2009-12-30 第一三共株式会社 カルボン酸化合物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
WO2012147516A1 (ja) 2011-04-28 2012-11-01 持田製薬株式会社 環状アミド誘導体
WO2012147518A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規３－ヒドロキシイソチアゾール １－オキシド誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8476287B2 (en) 2009-12-25 2013-07-02 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisothiazole derivative
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2014073904A1 (en) 2012-11-09 2014-05-15 Lg Life Sciences Ltd. Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
US10214521B2 (en) 2014-09-11 2019-02-26 Piramal Enterprises Limited Fused heterocyclic compounds as GPR120 agonists
US10227360B2 (en) 2014-02-19 2019-03-12 Piramal Enterprises Limited Compounds for use as GPR120 agonists
US10273230B2 (en) 2014-07-25 2019-04-30 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679908B (zh) * 2007-06-11 2012-10-24 奇华顿股份有限公司 有机化合物
CL2008003153A1 (es) * 2007-10-26 2009-07-24 Japan Tobacco Inc Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras.
ES2416462T3 (es) * 2009-06-29 2013-08-01 Merz Pharma Gmbh & Co. Kgaa Método de preparación de neramexane.
JP5749259B2 (ja) 2009-06-29 2015-07-15 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー １−クロロアセトアミド−１，３，３，５，５−ペンタメチルシクロヘキサンを調製する方法
BRPI1012669A2 (pt) * 2009-06-29 2016-04-05 Merz Pharma Gmbh & Co Kgaa metodo de preparacao de 3,3,5,5-tetrametliciclohexanona, método de preparção de 1-amino-1,3,3,5,5,-pentametilciclohexano ou um sal farmaceuticamente aceitável do mesmo e composto
EP2289881A1 (de) * 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
SG192216A1 (en) 2011-02-01 2013-09-30 Boehringer Ingelheim Int 9-[4-(3-chlor-2-fluor-phenylamino)-7-methoxy-quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, use thereof as a drug, and production thereof
EP2875020B1 (en) 2012-07-19 2017-09-06 Boehringer Ingelheim International GmbH Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
UY35143A (es) 2012-11-16 2014-05-30 Bristol Myers Squibb Co Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CA3058578A1 (en) * 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Aromatic compound
CN115181023B (zh) * 2022-05-17 2023-07-28 东华理工大学 螺环活性增塑剂及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005015461A (ja) * 2002-11-08 2005-01-20 Takeda Chem Ind Ltd 受容体機能調節剤
WO2005051373A1 (ja) * 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited 受容体機能調節剤
WO2006011615A1 (ja) * 2004-07-27 2006-02-02 Takeda Pharmaceutical Company Limited 糖尿病治療剤
JP2006083154A (ja) * 2003-12-25 2006-03-30 Takeda Chem Ind Ltd ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
WO2006127503A2 (en) * 2005-05-20 2006-11-30 Amgen Inc Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
WO2007033002A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JP2007525516A (ja) * 2004-02-27 2007-09-06 アムジエン・インコーポレーテツド 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4331179A1 (de) * 1993-09-14 1995-03-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
RU2191007C2 (ru) * 1996-05-24 2002-10-20 Лиганд Фармасьютикалз Инкорпорейтед Способ лечения иhcд агонистами rxr
GB9927056D0 (en) 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
DE60315776T2 (de) * 2002-10-14 2008-06-05 Firmenich S.A. Spiroverbindungen als Duftstoffe
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
EP2253315A1 (en) * 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
US7714008B2 (en) 2006-09-07 2010-05-11 Amgen Inc. Heterocyclic GPR40 modulators
AU2007292816B2 (en) 2006-09-07 2011-11-17 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
CL2008003153A1 (es) * 2007-10-26 2009-07-24 Japan Tobacco Inc Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras.
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005015461A (ja) * 2002-11-08 2005-01-20 Takeda Chem Ind Ltd 受容体機能調節剤
WO2005051373A1 (ja) * 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited 受容体機能調節剤
JP2006083154A (ja) * 2003-12-25 2006-03-30 Takeda Chem Ind Ltd ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
JP2007525516A (ja) * 2004-02-27 2007-09-06 アムジエン・インコーポレーテツド 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法
WO2006011615A1 (ja) * 2004-07-27 2006-02-02 Takeda Pharmaceutical Company Limited 糖尿病治療剤
WO2006127503A2 (en) * 2005-05-20 2006-11-30 Amgen Inc Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
WO2007033002A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2202216A4 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222281B2 (en) 2008-06-25 2012-07-17 Daiichi Sankyo Company, Limited Carboxylic acid compound
WO2009157418A1 (ja) * 2008-06-25 2009-12-30 第一三共株式会社 カルボン酸化合物
JP5425772B2 (ja) * 2008-06-25 2014-02-26 第一三共株式会社 カルボン酸化合物
US8476287B2 (en) 2009-12-25 2013-07-02 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisothiazole derivative
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
US8765752B2 (en) 2011-04-27 2014-07-01 Mochida Pharmaceutical Co., Ltd. 3-hydroxyisothiazole 1-oxide derivatives
WO2012147518A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規３－ヒドロキシイソチアゾール １－オキシド誘導体
US8557766B2 (en) 2011-04-27 2013-10-15 Mochida Pharmaceutical Co., Ltd. 3-hydroxyisothiazole 1-oxide derivatives
US8629102B2 (en) 2011-04-27 2014-01-14 Mochida Pharmaceutical Co., Ltd. 3-hydroxyisothiazole 1-oxide derivatives
US9072758B2 (en) 2011-04-28 2015-07-07 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2012147516A1 (ja) 2011-04-28 2012-11-01 持田製薬株式会社 環状アミド誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2014073904A1 (en) 2012-11-09 2014-05-15 Lg Life Sciences Ltd. Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
US10227360B2 (en) 2014-02-19 2019-03-12 Piramal Enterprises Limited Compounds for use as GPR120 agonists
US10273230B2 (en) 2014-07-25 2019-04-30 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
US10214521B2 (en) 2014-09-11 2019-02-26 Piramal Enterprises Limited Fused heterocyclic compounds as GPR120 agonists
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11555029B2 (en) 2018-02-13 2023-01-17 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11851429B2 (en) 2020-05-19 2023-12-26 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators

Also Published As

Publication number Publication date
CO6321230A2 (es) 2011-09-20
ME02338B (me) 2013-02-28
EP2202216A1 (en) 2010-06-30
KR101565622B1 (ko) 2015-11-03
SI2202216T1 (sl) 2012-10-30
IL205283A0 (en) 2010-12-30
US20090170908A1 (en) 2009-07-02
RU2010121160A (ru) 2011-12-10
CA2704013A1 (en) 2009-04-30
US20150299090A1 (en) 2015-10-22
TWI421070B (zh) 2014-01-01
MY148469A (en) 2013-04-30
CL2008003153A1 (es) 2009-07-24
AU2008314933B2 (en) 2013-05-02
JP4568779B2 (ja) 2010-10-27
CY1113352T1 (el) 2016-06-22
KR20100092456A (ko) 2010-08-20
EP2684861A2 (en) 2014-01-15
EP2684861A3 (en) 2014-05-07
US8299296B2 (en) 2012-10-30
EP2508503A1 (en) 2012-10-10
JP2010270137A (ja) 2010-12-02
TW200924742A (en) 2009-06-16
ZA201002305B (en) 2011-06-29
EP2202216A4 (en) 2010-11-24
ES2386596T3 (es) 2012-08-23
CN101835737B (zh) 2013-12-25
PT2202216E (pt) 2012-07-19
EP2202216B1 (en) 2012-06-27
US20130109710A1 (en) 2013-05-02
BRPI0818687A2 (pt) 2017-05-02
PE20091014A1 (es) 2009-08-17
JP2014221829A (ja) 2014-11-27
IL205283A (en) 2014-06-30
AU2008314933A1 (en) 2009-04-30
JP2016102130A (ja) 2016-06-02
PL2202216T3 (pl) 2012-11-30
JP2017132787A (ja) 2017-08-03
HK1144421A1 (en) 2011-02-18
CN101835737A (zh) 2010-09-15
AR071055A1 (es) 2010-05-26
HRP20120696T1 (hr) 2012-10-31
RU2490250C2 (ru) 2013-08-20
RS52474B (en) 2013-02-28
DK2202216T3 (da) 2012-09-10
MX2010004435A (es) 2010-05-13
JP2009120598A (ja) 2009-06-04
CA2704013C (en) 2015-12-22
NZ584161A (en) 2011-12-22

Similar Documents

Publication Publication Date Title
WO2009054479A1 (ja) スピロ環化合物及びその医薬用途
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
WO2010135524A8 (en) Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
WO2006067392A3 (en) Indole derivatives for the treatment of tuberculosis
WO2009017837A3 (en) Sublingual fentanyl spray
WO2008123469A1 (ja) ６員環アミド化合物およびその用途
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
IL205354A0 (en) Spiroindolinone derivatives
WO2012071509A3 (en) Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
WO2010128050A3 (en) Dihydroorotate - dehydrogenasee inhibitors as virostatic compounds
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
WO2010066629A3 (en) Novel azaindoles
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
WO2008058118A3 (en) Preparation of montelukast and its salts
IL217557A (en) Derivatives and Salts of 1-Oxo-4,9-Diazaspiro [5.5] Undec-4-Yel- (1,3-Thiazole-4-Yel) Methane
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2009140341A3 (en) Atorvastatin compositions
EP2581372A4 (en) CYANOCHINOLINDERIVATE
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880113238.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08841970

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008841970

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 584161

Country of ref document: NZ

Ref document number: 2008314933

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12010500785

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 1309/KOLNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008314933

Country of ref document: AU

Date of ref document: 20081024

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010040613

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 205283

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/004435

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2704013

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107011427

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10062839

Country of ref document: CO

Ref document number: 2010121160

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: PI 2010001866

Country of ref document: MY

NENP Non-entry into the national phase

Ref country code: JP

WWE Wipo information: entry into national phase

Ref document number: P-2012/0400

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0818687

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100422